Form 8-K - Current report:
SEC Accession No. 0001689813-22-000008
Filing Date
2022-01-10
Accepted
2022-01-10 06:59:30
Documents
14
Period of Report
2022-01-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bhvn-20220106.htm   iXBRL 8-K 32414
2 EX-99.1 a2021q4bhvnnetsalespre-ann.htm EX-99.1 21288
6 GRAPHIC image.jpg GRAPHIC 1168063
  Complete submission text file 0001689813-22-000008.txt   1804478

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bhvn-20220106.xsd EX-101.SCH 1920
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bhvn-20220106_lab.xml EX-101.LAB 23800
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bhvn-20220106_pre.xml EX-101.PRE 12508
8 EXTRACTED XBRL INSTANCE DOCUMENT bhvn-20220106_htm.xml XML 10525
Mailing Address 215 CHURCH STREET NEW HAVEN CT 06510
Business Address 215 CHURCH STREET NEW HAVEN CT 06510 203-404-0410
Biohaven Pharmaceutical Holding Co Ltd. (Filer) CIK: 0001689813 (see all company filings)

EIN.: 000000000 | State of Incorp.: D8 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38080 | Film No.: 22519616
SIC: 2834 Pharmaceutical Preparations